Special Issue

Chemical and Synthetic Biology Approaches in Cancer Immunotherapy

Message from the Guest Editors

Cancer immunotherapy is a promising and effective treatment strategy for different types of cancer in clinic. It is a broad concept that includes therapies based on antibodies, chimeric antigen receptor T cells, natural killer cells, bacteria, viruses, etc. Thus, interdisciplinary methods, such as chemical and synthetic biology approaches, facilitate the development of immuno-oncology. Recent chemical and synthetic biology advances have provided great opportunities for basic and translational studies of novel cancer immunotherapies, including the development of proteolysis targeting chimeric technology, molecular glues, etc., for mechanistic research, and the engineering of gene circuits in therapeutic cells.
This Special Issue aims to provide a broad survey of the most recent advances in the methodology development and applications of chemical and synthetic biology approaches in cancer immunotherapy. Original research articles or reviews focused on basic or translational studies that discuss new chemical probes, drug leads, cancer vaccines, methodologies, and synthetic biology systems for immuno-oncology are welcome.

Guest Editors

Dr. Qingfei Zheng

Department of Radiation Oncology, College of Medicine and Center for Cancer Metabolism, James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA

Dr. Qinglan Wang

Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu 610041, China

Deadline for manuscript submissions

closed (30 November 2023)

Molecules

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed

mdpi.com/si/129713

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

mdpi.com/journal/molecules

Molecules

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed

mdpi.com/journal/molecules

MDPI

About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt
Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).